Cargando…

Effectiveness of canakinumab treatment in Schnitzler's syndrome: a multi-center randomized placebo-controlled study

Detalles Bibliográficos
Autores principales:	Krause, K, Tsianakas, A, Wagner, N, Fischer, J, Weller, K, Metz, M, Maurer, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4597402/ http://dx.doi.org/10.1186/1546-0096-13-S1-O66

Ejemplares similares

Increasing the Interval of Canakinumab Administration Effectively Supports the Remission of Schnitzler's Syndrome
por: Gorodetskiy, Vadim R., et al.
Publicado: (2018)

A case of Schnitzler’s syndrome without monoclonal gammopathy successfully treated with canakinumab
por: Fujita, Yuya, et al.
Publicado: (2021)

Canakinumab leads to rapid reduction of neutrophilic inflammation and long-lasting response in Schnitzler syndrome
por: Bossart, Simon, et al.
Publicado: (2023)

The case of Schnitzler syndrome in one single rheumatologic center
por: Salugina, S, et al.
Publicado: (2015)

Canakinumab therapy in patients with Familial Mediterranean Fever
por: Ugurlu, S, et al.
Publicado: (2015)

Pharmacokinetics of Canakinumab in children younger than 2 years old with CAPS
por: Kalabus, J, et al.
Publicado: (2015)

Schnitzler syndrome and Schnitzler-like syndromes
por: Chu, Cong-Qiu
Publicado: (2022)

Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever
por: Horneff, G, et al.
Publicado: (2015)

Long-term efficacy and safety of Canakinumab in active Hyper-IgD syndrome (HIDS): results from an open-label study
por: Aróstegui, JI, et al.
Publicado: (2015)

Canakinumab treatment in patients with active recurrent or chronic TNF-receptor associated syndrome (TRAPS): Efficacy and safety results from a proof of concept study
por: Lachmann, H, et al.
Publicado: (2015)

The Schnitzler syndrome
por: Lipsker, Dan
Publicado: (2010)

Predictors of response in patients with active systemic JIA (SJIA) receiving canakinumab: an exploratory analysis of pooled 12-week data
por: Ruperto, N, et al.
Publicado: (2014)

12.4 ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS)
por: Kümmerle-Deschner, J, et al.
Publicado: (2008)

Skin and Systemic Inflammation in Schnitzler's Syndrome Are Associated With Neutrophil Extracellular Trap Formation
por: Bonnekoh, Hanna, et al.
Publicado: (2019)

Beyond Urticaria: Schnitzler Syndrome
por: Villaverde, Ricardo Ruiz, et al.
Publicado: (2017)

PReS-FINAL-2224: Canakinumab treatment regimens in CAPS-patients
por: Hofer, F, et al.
Publicado: (2013)

Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study
por: Ruperto, N, et al.
Publicado: (2011)

Canakinumab treat-to target strategies increase complete response rate in CAPS
por: Kuemmerle-Deschner, J, et al.
Publicado: (2015)

Schnitzler's Syndrome: A Case Report
por: Tinoco, Gabriel, et al.
Publicado: (2013)

Schnitzler Syndrome: A Recherche Entity
por: Kumar, Rajesh, et al.
Publicado: (2021)

Clinical symptoms and molecular investigations in 13 patients with Schnitzler syndrome identified at the single UK centre
por: Rowczenio, D, et al.
Publicado: (2015)

OR5-002 – In vitro studies in Schnitzler’s syndrome
por: De Koning, HD, et al.
Publicado: (2013)

PReS-FINAL-2330: Canakinumab treatment in patients with HIDS
por: Antón, J, et al.
Publicado: (2013)

Relationship between obesity and unrecognized myocardial infarction: a EuroCMR multi-center study
por: Jensen, Christoph J, et al.
Publicado: (2013)

Schnitzler’s syndrome: lessons from 281 cases
por: de Koning, Heleen D
Publicado: (2014)

Aortitis: A new feature of Schnitzler syndrome
por: Bursztejn, Anne-Claire, et al.
Publicado: (2017)

Schnitzler Syndrome: A Dramatic Response to Anakinra
por: Gouveia, Ana Isabel, et al.
Publicado: (2016)

Hereditary systemic autoinflammatory diseases and Schnitzler’s syndrome
por: Kacar, Mark, et al.
Publicado: (2019)

Schnitzler Syndrome after COVID-19 Vaccination
por: Asako, Mizuki, et al.
Publicado: (2022)

European Cardiovascular Magnetic Resonance (EuroCMR) registry - multi national tesults from 57 centers in 15 countries
por: Wagner, Anja, et al.
Publicado: (2013)

Canakinumab for the treatment of different refractory autoinflammatory disorders
por: Grein, Ingrid HR, et al.
Publicado: (2014)

The role of interleukin-1 beta in the pathophysiology of Schnitzler’s syndrome
por: de Koning, Heleen D., et al.
Publicado: (2015)

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)
por: Ruperto, N, et al.
Publicado: (2008)

PW03-008 – Mitochondrial disturbances in Schnitzler syndrome
por: Sediva, A, et al.
Publicado: (2013)

A multi-center trial of LGE-MRI of the left atrium
por: Kholmovski, Eugene, et al.
Publicado: (2013)

Canakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients
por: Wulffraat, NM, et al.
Publicado: (2014)

Clinical response to the canakinumab in crohn’s disease related artrhritis
por: Gündüz, Zübeyde, et al.
Publicado: (2014)

Clinical experiences with canakinumab as a treatment for autoinflammatory disorders
por: Saperia, C, et al.
Publicado: (2015)

Kidney involvement in the Schnitzler syndrome, a rare disease
por: Basile, Carlo, et al.
Publicado: (2017)

Schnitzler Syndrome: A Case Report and Review of Literature
por: Kim, Yoon Seob, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jl2jjc4oguf6784hdprjkmmmai